MedPath

Cysteamine

Generic Name
Cysteamine
Brand Names
Cystagon, Cystaran, Procysbi, Cystadrops
Drug Type
Small Molecule
Chemical Formula
C2H7NS
CAS Number
60-23-1
Unique Ingredient Identifier
5UX2SD1KE2
Background

Cystinosis is a rare disease caused by mutations in the CTNS gene that encodes for cystinosin, a protein responsible for transporting cystine out of the cell lysosome. A defect in cystinosin function is followed by cystine accumulation throughout the body, especially the eyes and kidneys.

Several preparations of cysteamine exist for the treatment of cystinosis manifestations, some in capsule form, and others in ophthalmic solution form. In particular, cystine deposits on the eye can cause significant discomfort throughout the day and require frequent treatment with eye drops, typically every waking hour.

On August 25th 2020, the first ophthalmic solution for cystinosis requiring only 4 daily treatments was granted FDA approval. Cysteamine eye drops are a practical and effective option for those affected by ocular cystinosis. Marketed by Recordati Rare Diseases Inc., CYSTADROPS® reduce the burden of multiple frequent medications normally administered to those with cystinosis.

Indication

The bitartrate salt of cysteamine is used for the oral treatment of nephropathic cystinosis and cystinuria in adults and children ≥6 years old. The hydrochloride salt, used in eye drop preparations, is indicated for the treatment of corneal cystine crystal accumulation in patients with cystinosis.

Associated Conditions
Cystinosis, Nephropathic, Corneal cystine crystal accumulation
Clinical Trials
Related News

Thiogenesis Launches Phase 2 Trial of TTI-0102 for MELAS, a Rare Mitochondrial Disease

• Thiogenesis Therapeutics has dosed the first two patients in its Phase 2 clinical trial of TTI-0102 for MELAS, a rare inherited mitochondrial disease with no approved treatments in the EU or US. • The randomized, double-blind, placebo-controlled trial will enroll 12 patients across centers in the Netherlands and France, with endpoints including walking ability, fatigue severity, and quality of life. • TTI-0102 is a prodrug designed to increase intracellular levels of glutathione and taurine, both deficient in MELAS patients, potentially addressing the underlying oxidative stress contributing to the disease.

Novel Smart Capsule Technology Could Revolutionize Multi-Medication Regimens

• UC San Diego researchers have developed an innovative timed-release capsule that can deliver multiple medications at specific intervals throughout the day from a single dose. • The smart capsule utilizes pH-sensitive barriers and microscopic magnesium particles to control drug release timing, with initial tests successfully delivering three timed doses of levodopa for Parkinson's disease management. • All materials used in the capsule are FDA-approved, potentially accelerating the path to market for a technology that could significantly improve medication adherence and treatment efficacy for patients with complex dosing schedules.

Amgen Reports Strong Global Demand in Q1 2025, Bolstering Long-Term Growth Outlook

• Amgen announced positive first quarter 2025 financial results, citing strong global demand across its product portfolio and successful new product launches. • Chairman and CEO Bob Bradway expressed confidence in Amgen's long-term growth prospects, supported by recent successful Phase 3 clinical trial results for several products. • The biotechnology company, which employs over 28,000 people globally, continues to focus on its mission of harnessing biology and technology to combat serious diseases.

EMA Recommends Approval for New Cancer Treatments and Vaccines

• The European Medicines Agency (EMA) has recommended eight new products for EU-wide approval, expanding treatment options for various conditions. • Several cancer treatments have received positive recommendations, potentially offering new hope for patients with different types of malignancies. • A new antiparasitic combination has been endorsed for use in non-EU markets, addressing a critical need in regions affected by parasitic infections. • The EMA is also reviewing new safety information regarding Leqembi, an Alzheimer's disease treatment, ensuring ongoing monitoring of its benefit-risk profile.

Huntington's Disease: Optimism Surrounds Potential Breakthroughs in 2025

• uniQure's gene therapy trial has shown promising results, with treated patients exhibiting a significant reduction in the rate of Huntington's disease progression. • The FDA has endorsed the use of neurofilament light (NfL) as a biomarker and composite UHDRS (cUHDRS) as a clinical endpoint, potentially accelerating drug approvals. • PTC Therapeutics anticipates full results from its huntingtin-lowering drug, votoplam, in early summer, with potential for conditional approval if results are strong. • Research is focusing on novel biomarkers, such as imaging markers for huntingtin protein and markers for CAG expansion, to enhance therapeutic development.

Thiogenesis Receives EMA Clearance to Initiate Phase 2 Trial of TTI-0102 for MELAS

• Thiogenesis Therapeutics has received EMA clearance to begin a Phase 2 clinical trial for TTI-0102 in patients with MELAS. • The Phase 2 trial is a multi-country, randomized, double-blind, placebo-controlled study that will enroll 12 patients in France and the Netherlands. • TTI-0102 is a prodrug designed to increase intracellular levels of glutathione and taurine, which are deficient in MELAS patients. • The trial will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of TTI-0102 over a 6-month period.

Cysteamine Ophthalmic Solution Shows Promise in Japanese Cystinosis Patients

• A Phase III study in Japan evaluated cysteamine hydrochloride 0.55% ophthalmic solution for treating corneal cystine crystals in cystinosis patients. • The study showed a decrease in corneal crystal density and improvement in photophobia, suggesting potential efficacy in Japanese patients. • The ophthalmic solution demonstrated an acceptable safety profile, with most adverse events being eye-related and manageable. • These findings support the use of cysteamine eye drops for managing ocular manifestations of cystinosis, a rare genetic disorder.

NCFB Pipeline Shows Promise with Over 15 Companies Developing New Therapies

• The non-cystic fibrosis bronchiectasis (NCFB) market is experiencing growth due to rising prevalence and increased awareness, leading to early diagnosis and treatment. • Over 15 companies are actively developing more than 15 NCFB drugs, aiming to improve the treatment landscape for this chronic lung condition. • Key players like Insmed, AstraZeneca, and Verona Pharma are advancing promising therapies such as brensocatib, benralizumab and ensifentrine through clinical trials. • Recent clinical trial milestones, including Phase III results for brensocatib and Phase II enrollment for AP-PA02, signal progress in addressing unmet needs in NCFB treatment.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy